Caribou Biosciences (CRBU) Competitors

Sangamo Therapeutics (NASDAQ:SGMO) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk.

Do analysts prefer SGMO or CRBU?

Sangamo Therapeutics currently has a consensus price target of $2.67, indicating a potential upside of 219.90%. Caribou Biosciences has a consensus price target of $11.25, indicating a potential upside of 435.71%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Sangamo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Caribou Biosciences	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media refer more to SGMO or CRBU?

In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 2 articles in the media. Sangamo Therapeutics' average media sentiment score of 0.69 beat Caribou Biosciences' score of 0.67 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caribou Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, SGMO or CRBU?

Sangamo Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.

Which has higher valuation & earnings, SGMO or CRBU?

Caribou Biosciences has lower revenue, but higher earnings than Sangamo Therapeutics. Caribou Biosciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$176.23M	0.98	-$257.83M	-$1.86	-0.45
Caribou Biosciences	$33.11M	5.73	-$102.07M	-$1.45	-1.45

Is SGMO or CRBU more profitable?

Caribou Biosciences has a net margin of -372.78% compared to Sangamo Therapeutics' net margin of -2,033.69%. Caribou Biosciences' return on equity of -34.76% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-2,033.69%	-273.25%	-134.24%
Caribou Biosciences	-372.78%	-34.76%	-29.58%

Do institutionals and insiders hold more shares of SGMO or CRBU?

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer SGMO or CRBU?

Sangamo Therapeutics received 420 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 62.43% of users gave Sangamo Therapeutics an outperform vote while only 57.89% of users gave Caribou Biosciences an outperform vote.

Company	Underperform	Outperform
Sangamo Therapeutics	Outperform Votes 442 62.43%	Underperform Votes 266 37.57%
Caribou Biosciences	Outperform Votes 22 57.89%	Underperform Votes 16 42.11%

Summary

Caribou Biosciences beats Sangamo Therapeutics on 12 of the 17 factors compared between the two stocks.